1G |
1st generation |
2G |
2nd generation |
3G |
3rd generation |
4G |
4th generation |
AAV |
Adeno-associated virus |
ACT |
Adoptive cell therapy |
AICD |
Activation induced cell death |
ALL |
Acute lymphoblastic leukemia |
APCs |
Antigen presenting cells |
BCAP |
B cell adaptor for phosphoinositide 3-kinase |
BCMA |
B cell maturation antigen |
BCR |
B cell receptor |
BET |
Bromodomain and extra-terminal motif |
CAR |
Chimeric antigen receptor |
CLL |
Chronic lymphocytic leukemia |
CTLA-4 |
Cytotoxic T-lymphocyte-associated Protein 4 |
DCs |
Dendritic cells |
DLBCL |
Diffuse large B cell lymphoma |
EMA |
European Medicines Agency |
FDA |
Food and Drug Administration |
GMP |
Good manufacturing practice |
HLA |
Human leukocyte antigen |
ICOS |
Inducible T cell costimulator |
IL |
Interleukin |
ITAM |
Immunoreceptor tyrosine-based activation motif |
NHL |
Non-Hodgkin lymphoma |
LAG-3 |
Lymphocyte-activation gene-3 |
PB |
Peripheral blood |
PBMC |
Peripheral blood mononuclear cells |
PD-1 |
Programmed cell death protein 1 |
PI3K |
Phosphoinositide 3-kinase |
PMBCL |
Primary mediastinal B cell lymphoma |
r/r |
relapsed/refractory |
scFv |
Single chain variable fragment |
TAA |
Tumor-associated antigen |
TCR |
T cell receptor |
TCM cell |
Central memory-like T cell |
TEff cell |
Effector-like T cell |
TEM cell |
Effector memory-like T cell |
TGFβ |
Transforming growth factor β |
Th cell |
T helper cell |
TILs |
Tumor-infiltrating lymphocytes |
TIM-3 |
T cell immunoglobulin and mucin-domain containing-3 |
TN cell |
Naïve-like T cell |
TM |
Transmembrane |
TRAC |
T cell receptor α constant |
Treg cell |
Regulatory T cell |
TRUCK |
T cells redirected for universal cytokine killing |
TSCM cell |
Stem cell memory-like T cell |
VIP |
Vasoactive intestinal peptide |